Pharmacogenetics and Aromatase Inhibitor Induced Side Effects in Breast Cancer Patients

References

• Dowsett M , CuzickJ , IngleJet al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen . J. Clin. Oncol.28 ( 3 ), 509 – 518 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Cuzick J , SestakI , BaumMet al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial . Lancet Oncol11 ( 12 ), 1135 – 1141 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• BIG 1–98 Collaborative Group : MouridsenH , Giobbie-HurderA , GoldhirshAet al.Letrozoletherapyalone or in sequence with Tamoxifen in women with breast cancer . N. Engl. J. Med.361 ( 8 ), 766 – 776 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Coombes RC , HallE , GibsonLJet al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer . N. Engl. J. Med.350 ( 11 ), 1081 – 1092 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Dubsky PC , JakeszR , MlineritschBet al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the austrian breast and colorectal cancer study group . J. Clin. Oncol.30 ( 7 ), 722 – 728 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kaufmann M , JonatW , HilfrichJet al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study . J. Clin. Oncol.25 ( 19 ), 2664 – 2670 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Aihara T , TakatsukaY , OhsumiSet al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study . Breast Cancer Res. Treat.121 ( 2 ), 379 – 387 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Boccardo F , RubagottiA , GuglielminiPet al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial . Ann. Oncol.17 ( 7 ), vii10 – vii14 ( 2006 ).
   PubMedGoogle Scholar
• Goss PE , IngleJN , MartinoSet al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer . N. Engl. J. Med.349 ( 19 ), 1793 – 1802 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Jakesz R , GreilR , GnantMet al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a . J. Natl Cancer Inst.99 ( 24 ), 1845 – 1853 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mamounas EP , JeongJ-H , WickerhamDLet al. Benefit from exemestane as extended adjuvant therapy following five years of adjuvant tamoxifen: intent-to-treat analysis of the national surgical adjuvant breast and bowel project b-33 trial . J. Clin. Oncol.26 ( 12 ), 1965 – 1971 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Burstein HJ , TerminS , AndersonHet al. Adjuvant endocrine therapy for women with hormone-receptor positive breast cancer: american society of clinical oncology clinical practice guideline focused update . J. Clin. Oncol.32 ( 21 ), 2255 – 2269 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Amir E , SerugaB , NiraulaS , CarlssonL , OcañaA . Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis . J. Natl Cancer Inst.103 ( 17 ), 1299 – 1309 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) , DowsettM , ForbesJF , BradleyRet al.Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials . Lancet.386 ( 10001 ), 1341 – 1352 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Goss PE , IngleJN , PritchardKIet al. Extending aromatase-inhibitor adjuvant therapy to 10 years . N. Eng. J. Med.375 , 209 – 219 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Dunning AM , DowsettM , HealeyCSet al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women . J. Natl Cancer Inst.96 , 936 – 945 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wang L , EllsworthKA , MoonIet al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors . Cancer Res.70 , 319 – 328 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Garcia-Casado Z1 , Guerrero-ZotanoA , Llombart-CussacAet al. A polymorphism at the 3’-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole . BMC Cancer10 , 36 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lunardi G , PiccioliP , BruzziPet al. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole . Breast Cancer Res. Treat.137 ( 1 ), 167 – 174 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• López-Knowles E , WilkersonPM , RibasRet al. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer . Breast Cancer Res.17 ( 1 ), 35 ( 2015 ).
   PubMedGoogle Scholar
• Colomer R , MonzoM , TusquetsIet al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma . Clin. Cancer Res.14 ( 3 ), 811 – 816 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Liu L , BaiYX , ZhouJHet al. A polymorphism at the 3’-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma . Int. J. Mol. Sci.14 ( 9 ), 18973 – 18988 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ghimenti C , Mello-GrandM , GrossoEet al. Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy . Exp. Ther. Med.5 ( 3 ), 902 – 906 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R , ArnedosM , HadfieldKDet al. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients . Breast Cancer Res. Treat.133 ( 3 ), 1191 – 1198 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Napoli N , RastelliA , MaCet al. Geneticpolymorphism at Val80 (rs700518) of the CYP19A1 geneisassociatedwith aromatase inhibitorassociatedboneloss in womenwith ER (+) breast cancer . Bone55 , 309 – 314 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Oesterreich S , HenryNL , KidwellKMet al. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover . Breast Cancer Res. Treat.154 ( 2 ), 263 – 273 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B , GrayKP , AbramovitzMet al. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial . Breast Cancer Res. Treat.151 ( 2 ), 373 – 384 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mazzuca F , BotticelliA , MazzottiEet al. CYP19A1 genetic polymorphisms rs4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy: a pilot study . Eurasian J. Med.48 ( 1 ), 10 – 14 ( 2016 ).
   PubMedGoogle Scholar
• Gervasini G , JaraC , OlierC , RomeroN , MartínezR , CarrilloJA . Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients . Br. J. Clin. Pharmacol.83 ( 3 ), 562 – 571 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Fontein DYB , HoutsmaD , NortierJWRet al. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial . Breast Cancer Res. Treat.144 ( 3 ), 599 – 606 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mao JJ , SuHI , FengRet al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors . Breast Cancer Res.13 ( 1 ), R8 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Johansson H , GrayKP , PaganiOet al. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial . Breast Cancer Res.18 ( 1 ), 110 ( 2016 ).
   PubMedGoogle Scholar
• Santa-Maria CA , BlackfordA , NguyenATet al. Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy . Clin. Cancer Res.22 ( 6 ), 1395 – 1402 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Wang J , LuK , SongYet al. RANKL and OPG polymorphisms are associated with aromatase inhibitor-related musculoskeletal adverse events in Chinese Han breast cancer patients . PLoS ONE10 ( 7 ), e0133964 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Henry NL , SkaarTC , DantzerJet al. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer . Breast Cancer Res. Treat.138 ( 3 ), 807 – 816 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Koukouras D , MarioliDJ , PapadopoulosKet al. Association of estrogen receptor alpha (ERα) gene polymorphisms with endometrial thickness and lipid profile in women with aromatase inhibitors . J. Gyn. Endocrinol.28 ( 11 ), 859 – 862 ( 2012 ).
   Google Scholar
• Servitja S , MartosT , Rodriguez SanzMet al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance . Ther. Adv. Med. Oncol.7 ( 5 ), 291 – 296 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Garcia-Giralt N , Rodríguez-SanzM , Prieto-AlhambraDet al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study . Breast Cancer Res. Treat.140 ( 2 ), 385 – 395 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Sanz M , Garcia-GiraltN , Prieto-AlhambraDet al. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss . J. Mol. Endocrinol.55 ( 1 ), 69 – 79 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lintermans A , Van AstenK , JongenLet al. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients . Eur. J. Cancer56 , 31 – 36 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Liu M , WangL , BongartzTet al. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression . Breast Cancer Res.14 ( 2 ), R41 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ingle JN , SchaidDJ , GossPEet al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors . J. Clin. Oncol.28 ( 31 ), 4674 – 4682 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Haiman CA , DossusL , SetiawanVWet al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women . Cancer Res.67 ( 5 ), 1893 – 1897 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Xiong J , O’BrienCA . Osteocyte RANKL: new insights into the control of bone remodeling . J. Bone Miner. Res.27 ( 3 ), 499 – 505 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Boyce BF , XingL . Functions of RANKL/RANK/OPG in bone modeling and remodeling . Arch. Biochem. Biophy.473 ( 2 ), 139 – 146 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Dougall WC . Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the pathway in tumorigenesis and metastasis . Clin. Cancer Res.18 ( 2 ), 326 – 335 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Liu M , GossPE , IngleJNet al. Aromatase inhibitor associated bone fractures: a case cohort GWAS and functional genomics . Mol. Endocrinol.28 ( 10 ), 1740 – 1751 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gennari L , MerlottiD , De PaolaVet al. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: aHuGE review . Am. J. Epidemiol.161 ( 4 ), 307 – 320 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wang J , LuK , SongYet al. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer . PLoS ONE8 ( 7 ), e68798 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ruddy K , MayerE , PartridgeA . Patient adherence and persistence with oral anticancer treatment . CA Cancer J. Clin.59 ( 1 ), 56 – 66 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Crew KD , GreenleeH , CapodiceJet al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer . J. Clin. Oncol.25 ( 25 ), 3877 – 3883 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Henry NL , GilesJT , StearnsV . Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management . Oncology22 ( 12 ), 1401 – 1408 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hadji P , JackischC , BoltenWet al. COMPliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy . Ann. Oncol.25 ( 2 ), 372 – 377 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pan H , GrayRG , DaviesCet al. Predictors of recurrence during years 5–14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET) . J. Clin. Oncol.34 ( Suppl. ), Abstr 505 ( 2016 ).
   Google Scholar
• Mamounas EP , BandosH , LemberskyBCet al. A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42. S1–05 . Presented at : San Antonio Breast Cancer Symposium . San Antonio, TX, USA , 19 December 2016 .
   Google Scholar
• Tjan-Heijnen VC , Van HellemondIE , PeerPGet al. First results from the multicenter Phase III DATA study comparing 3 versus 6 years of anastrozole after 2–3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. S1–03 . Presented at : San Antonio Breast Cancer Symposium . San Antonio, TX, USA , 19 December 2016 .
   Google Scholar
• Blok EJ , van de VeldeCJH , Meershoek-Klein KranenbargEMet al. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–2005). S1–04 . Presented at : San Antonio Breast Cancer Symposium . San Antonio, TX, USA , 19 December 2016 .
   Google Scholar
• Lonning PE . The potency and efficacy of aromatase inhibitors across the breast cancer continuum . Ann. Oncol.22 ( 3 ), 503 – 514 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Confavreux CB , FontanaA , GuastallaJP , MunozF , BrunJ , DelmasPD . Estrogen dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates . Bone41 ( 3 ), 346 – 352 ( 2007 ).
   PubMed Web of Science ®Google Scholar